Skip to main content

Table 3 Burden of DPR and aDMA by region in clinicopathologic subgroups

From: Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease

  FCtx DF CA4 CA2/3 MCtx
  poly-GA
FTLD 6.4 (3.8, 9.4) 310 (110, 470) 6 (4.1, 9.5) 5.6 (4.5, 8.3) 5.8 (3.7, 12)
FTLD-MND 7.5 (5.6, 15) 420 (320, 630) 9.5 (6.6, 13) 9.7 (4.7, 15) 14 (6.2, 17)
MND 7.4 (5.8, 13) 380 (280, 480) 10 (7.4, 14) 8.2 (3.0, 12) 9.3 (6.5, 13)
  poly-GP
FTLD 9.7 (5.9,14) 120 (71, 262) 8 (6.7, 13) 19 (13, 33) 10 (6.7, 13)
FTLD-MND 13 (11, 18) 180 (98, 270) 13 (7.4, 18) 31 (19, 39) 10 (8.0, 14)
MND 10 (6.6, 16) 130 (86, 230) 13 (10, 17) 27 (16, 39) 11 (4.9, 18)
  poly-GR
FTLD 3.0 (2.2, 4.2) 16 (9.5, 48) 3.0 (2.3, 5.6) 5.1 (3.3, 9.3) 2.6 (1.3, 5.5)
FTLD-MND 6.8 (3.7, 9.5)* 49 (26, 86)* 8.5 (6.8, 12)* 17 (11, 26)* 4.7 (3.1, 7.9)
MND 2.9(1.1, 3.4) 26 (18, 51) 7.5 (4.7, 8.8) 12 (3.7, 22) 2.6 (1.2, 4.9)
  aDMA
FTLD 3.3 (2.8, 4.7) 83 (31, 100) 10 (6.8, 14) 16 (10, 37) 3.4 (2.1, 5.6)
FTLD-MND 5.5 (3.1, 8.2) 77 (21, 140) 17 (14, 22)* 25 (17, 36) 5.6 (4.6, 6.8)
MND 4.0 (2.1, 7.4) 53 (31, 81) 15 (12, 20) 15 (6, 29) 3.5(2.5, 5.6)
  1. In frontal cortex, p < 0.001, FTLD vs. FTLD-MND, p = 0.005, FTLD-MND v.s MND. In DF, p = 0.02, FTLD vs. FTLD-MND. In CA4, p = 0.002, FTLD vs. FTLD-MND. In CA2/3, p = 0.003, FTLD vs. FTLD-MND. All variables analyzed with Kruskal-Wallis ANOVA on Ranks and data are displayed as median (25th and 75th range)
  2. *Statistically significant p-value (p < 0.05); all p-value for ANOVA on Ranks comparison of all three groups
  3. FCtx frontal cortex, MCtx Motor cortex, DF dentate fascia, CA (cornu ammonis)